Full-Time
Posted on 8/23/2024
AI-driven drug discovery platform
$210k - $250k/yr
Senior, Expert
Remote in USA
Remote option available.
Upload your resume to see how it matches 18 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Atomwise uses artificial intelligence to enhance drug discovery in the pharmaceutical industry. Its main product is an AI engine that employs machine learning and convolutional neural networks to analyze extensive chemical libraries. This technology allows Atomwise to identify new small molecule medicines more efficiently than traditional methods. The company primarily serves clients in healthcare and pharmaceuticals, focusing on developing and co-developing drug pipeline assets, which are funded by investors. Atomwise stands out from competitors by combining AI and machine learning to accelerate the drug discovery process, ultimately aiming to reduce costs and improve patient outcomes with more effective treatments.
Company Size
11-50
Company Stage
N/A
Total Funding
$196.7M
Headquarters
San Francisco, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision
FSA
401k
Parental leave
Commuter benefits
Professional development
SAN FRANCISCO-(BUSINESS WIRE)-Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the appointment of Steve Worland, Ph.D. as Chief Executive Officer and member of the Board of Directors.
SAN FRANCISCO--(BUSINESS WIRE)--Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations with over 250 academic labs across 30 countries, representing the largest and most comprehensive virtual HTS campaign reported to date. In a paper published in Nature Scientific Reports, AtomNet successfully identified structurally novel hits for 235 of 318 targets evaluated, representing a significant improvement in hit success rate over traditional HTS. AtomNet demonstrated consistently high hit rates across all target classes, which covered a wide breadth of protein classes relevant across major therapeutic areas, confirming the broad applicability of the AI platform. AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target. Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery
Atomwise has hired Neely Mozaffarian as its chief medical officer, CEO Abraham Heifets told Endpoints News in an exclusive interview on his company's future.
An active A.I. driven drug development company since the beginning, Atomwise recently introduced A.I. based 'AtomNet PoseRanker (ANPR)' with improved performance.
SAN FRANCISCO--(BUSINESS WIRE)--Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery across a range of therapeutic areas. He was instrumental in the discovery and development of lorpucitinib and mivatonib, and is co-inventor of vaborbactam, which was approved by the U.S. Food and Drug Administration in combination with meropenem. Most recently, Dr. Hirst served as Interim CSO of Turning Point Therapeutics, which was acquired in August by Bristol Myers Squibb for $4.1 billion. “At Atomwise, we continue to reimagine how drug discovery should be done, now that our AI-enabled engine allows us to interrogate novel chemical space and gives us the potential to drug challenging targets,” said Abraham Heifets, Ph.D., Co-Founder and CEO of Atomwise. “Gavin brings deep expertise in structure- and fragment-based drug discovery, and a fantastic track record in driving those initial discoveries to become new medicines to help patients. We are thrilled that he is joining our team.”